Salute e Benessere

Global Consortium Identifies Novel Parkinson's Genetic Risk Factor in African…

The discovery of a novel GBA1 variant came from a comprehensive first-of-its-kind genome-wide assessment led by GP2 in 1,488 people with PD and 196,430 control volunteers of African and African admixed ancestry. Most participants were part of (i) the Nigerian Parkinson Disease Research Network, (ii) the U.S.-based Black and African American Connections to Parkinson's Disease (BLAAC PD) study, (iii) the 23andMe research community. Analysis of genomic data was led by scientists at the NIH's Center…
PR Newswire
24/08/2023

Vittra APS Unique composite by FGM is appointed as a solution to a clinical…

According to evaluator, the composite provides that blocking-out ability without having According to evaluator, the composite provides that blocking-out ability without having to stock a base material in your office. Due to the APS technology (advanced polymerization system) working time is extended. "This material truly is "Unique" in that it will minimize your material stocking as it is one shade adapting to all shades, and will give you a color blend," says Prince. The…
PR Newswire
24/08/2023

Philips integrates AI in cardiac ultrasound and across cardiac care at ESC 2023

Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today highlighted how it integrates AI in cardiac ultrasound and across cardiac care to help improve clinical confidence and increase efficiency. Center-stage at the European Society of Cardiology (ESC , Aug. 25-28, Amsterdam) Congress is the portable Philips Ultrasound Compact System 5500 CV , which includes an AI-powered automation tool (the automated strain quantification)...
Nasdaq GlobeNewswire
24/08/2023

Alloksys reports interim results of its clinical phase IIb trial with Alkaline…

The prospective, randomized, double-blind, and placebo-controlled study was conducted in multiple centers inEuropeand theAsia/Pacificregion. The subgroup with a normal renal filtration rate that clearly benefited from RESCAP ®administration, constituted approximately 50% of the total cohort. These outcomes warrant a follow-up clinical phase III trial with a total of 400 patients, to commence Q3 2023. Ruud Brands, Founder and CEO of Alloksys, comments on the interim...
PR Newswire
24/08/2023

OMRON Healthcare Sponsors ESC Congress 2023

Image: Exhibition booth (for illustration purposes only)https://cdn.kyodonewsprwire.jp/prwfile/release/M000242/202308228313/_prw_PI2lg_1IFJHtMm.jpg Image: Exhibition booth (for illustration purposes only)https://cdn.kyodonewsprwire.jp/prwfile/release/M000242/202308228313/_prw_PI2lg_1IFJHtMm.jpg Under the theme of "Revealing asymptomatic atrial fibrillation and hypertension in the fight against stroke," the satellite symposium will be chaired by Prof.Gerhard Hindricksof Charite...
PR Newswire
24/08/2023

Implantica publishes Interim Report January - June 2023 (Q2)

Significant events after the end of the period Significant events after the end of the period Financial summary second quarter 2023 First six months Telephone conference Implantica will hold a teleconference on24 August 2023at 15:00 (CEST) withPeter Forsell(CEO), Andreas Öhrnberg (CFO), andNicole Pehrsson(Chief Corporate Affairs Officer). Please see the dial-in details below to join the conference: Webcasthttps://ir.financialhearings.com/implantica-q2-2023...
PR Newswire
24/08/2023

XNK Therapeutics enters into research collaboration with Karolinska University…

"We look forward to conducting this important study together with the group of Dr Martin Jädersten, Medical lead for AML at the Karolinska University Hospital. The study will evaluate our product candidate XNK02 as a novel therapy for patients with AML, for which new treatment modalities are desperately needed," said Dr Tim D'Alessandri, senior scientist and project leader at XNK. "We look forward to conducting this important study together with the group of DrMartin Jädersten…
PR Newswire
24/08/2023

Pharming Group to participate in September investor conferences

About Pharming Group N.V. About Pharming Group N.V. Pharming Group N.V. (Euronext Amsterdam: PHARM/Nasdaq: PHAR) is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. Pharming is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines, including small molecules, biologics, and gene therapies that are in early to late-stage development. Pharming is...
PR Newswire
24/08/2023

Mithra prices private placement to raise EUR 20 million in equity

THIS ANNOUNCEMENT IS NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD BE PROHIBITED BY APPLICABLE LAW Mithra prices private placement to raise EUR 20 million in equity Liege, Belgium,24 August 2023 –07:30 CEST– Mithra Pharmaceuticals SA (Euronext Brussels: MITRA) (the "Company" or "Mithra"), a company dedicated to Women's Health, announces today that it...
Nasdaq GlobeNewswire
24/08/2023

BioSenic receives a Chinese patent with broad claims, protecting the combined…

INSIDE INFORMATION Composition-of-matter patent covers the therapeutic use of arsenic salts and metal ions through various routes of administrationEnriched IP portfolio protects ATO with demonstrated therapeutic potential for indications ranging from cancer to immune or infectious diseases Mont-Saint-Guibert, Belgium, 24 August, 2023, 7.00am CET – BioSenic (Euronext Brussels and Paris: BIOS), the clinical-stage company specializing in serious autoimmune and inflammatory...
Nasdaq GlobeNewswire
24/08/2023

Press Release Biocartis Group NV: Biocartis Announces 2023 Half-Year Results on…

PRESS RELEASE: 24 August 2023 , 07:00 CEST BIOCARTIS ANNOUNCES 2023 HALF-YEAR RESULTS ON 26SEPTEMBER 2023Mechelen, Belgium,24 August 2023 –Biocartis Group NV (the 'Company' or 'Biocartis'), an innovative molecular diagnostics company (Euronext Brussels: BCART), announces today that it will report its 2023 half-year results and provide further updates on the status of its reorganization and financing & recapitalization plans on 26...
Nasdaq GlobeNewswire
24/08/2023

PeptiGrowth Inc. and Orizuru Therapeutics, Inc. Enter into Joint Development of…

PeptiGrowth is developing "synthetic peptide growth factors" that have the same functions as commercially available growth factors and cytokines by utilizing their proprietary peptide discovery technology: Peptide Discovery Platform System (PDPS). PeptiGrowth aims to contribute to expansion of the regenerative medicine and cell therapy industry by developing "synthetic peptide growth factors", thereby solving the problems of standards for biologically derived raw materials…
PR Newswire
24/08/2023

Salvia BioElectronics: First-Ever Patient Treated with Breakthrough…

Bioelectronic foilsWhile many people with migraine and cluster headache can be treated using current medical methods, a significant number of patients do not find relief and are in desperate need of effective treatment. Bioelectronic foilsWhile many people with migraine and cluster headache can be treated using current medical methods, a significant number of patients do not find relief and are in desperate need of effective treatment. Recognizing this unmet need, Salvia BioElectronics...
PR Newswire
23/08/2023

Contraceptives Global Market Exhibit Growth at a CAGR of ~5% by 2027 |…

Key Takeaways from the Contraceptives Market Report Key Takeaways from the Contraceptives Market Report To read more about the latest highlights related to the contraceptives market, get a snapshot of the key highlights entailed in theGlobal Contraceptives Market Report Contraceptives Overview Contraceptives are a diverse range of medical methods and devices designed to prevent unintended pregnancies by interfering with the process of conception. These tools help individuals...
PR Newswire
23/08/2023

MDxHealth Reports Q2 and Half Year 2023 Results

NEWS RELEASE –REGULATED INFORMATION 23AUGUST2023 , 4:00PM EDT / 22:00 CET MDxHealth ReportsQ2 and Half Year 2023 Results Year-over-yearQ2 revenues increase by 143% to $16 .7million;excluding GPS, revenues up 29% Q2 gross margin expandedto 59.7% up from 42.4% in the prior year periodAmendedGPS purchase agreement with Exact Sciences defersCompany's earn-out payment period from...
Nasdaq GlobeNewswire
23/08/2023

Invitation to Immunovia's Q2 presentation

Telephone numbers and webcast Telephone numbers and webcast Call any of the numbers below to participate via telephone. Please dial in a few minutes before the presentation starts. Sweden : +46 (0)8 5051 0031United Kingdom : +44 (0) 207 107 06 13United States : +1 (1) 631 570 56 13 Link to the webcast: https://link.edgepilot.com/s/55898572/0v6JeODzJ0OaR5rjK1wJ1g?u=https://creo-live.creomediamanager.com/0916b506-5ec6-4678-b83a-ab16e40022e3 A recording of the presentation...
PR Newswire
23/08/2023

Information on the Total Number of Voting Rights (Denominator) following…

Regulated Information - Denominator Atlas Special Opportunities, LLChas converted 8convertible bonds in Oxurion resulting in a EUR 200 ,000capital increase. This is part of Atlas Special Opportunities, LLC's EUR 20 million Capital Commitment1 that will allow Oxurion to focus on progressing its novel and differentiated back of the eye drug candidate targeting potential market opportunities of over USD 5billion.Leuven, BELGIUM ,Boston, MA, US–...
Nasdaq GlobeNewswire
23/08/2023

Oxurion Receives Transparency Notifications from Atlas Special Opportunities LLC

Regulated InformationLeuven, BELGIUM, Boston, MA, US – August23 , 2023 – 8 .00PM CETOxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, today announced that, pursuant to Belgian Transparency legislation 1it has received transparency notifications as follows: Oxurion received a first transparency notification on August...
Nasdaq GlobeNewswire
23/08/2023

Cellares Raises $255M Series C to Launch First Integrated Development and…

Cellares will use the new funding to launch the world's first commercial-scale IDMO Smart Factory, which seamlessly integrates advanced robotics, purpose-built technology, and interconnected software. The 118,000 sq. ft. IDMO Smart Factory, located in Bridgewater, New Jersey, will be capable of producing 40,000 cell therapy batches per year[1]. By leveraging integrated technologies, IDMO Smart Factories can produce 10 times more cell therapy batches per year than traditional CDMO facilities…
PR Newswire
23/08/2023

Ramsay Sante : provisional annual results at end of June 2023

PRESS RELEASE Paris, 23 rdAugust 2023 Provisional annual results at the endof June 2023Group revenue increasedby 9.3% to €4.7bn supported by positive activity volume growth in all geographies and recent acquisitions in the Nordic countries . Revenue growth on a like-for-like basis of 7.0%.Group EBITDA decreasedby 5.6% to €621.4m , impacted by lower subsidies , high salary and procurement inflation and...
Nasdaq GlobeNewswire
23/08/2023

Tiziana Life Sciences Announces Appointment of William A. Clementi as Chief…

Leadership Addition Strengthens Company's Commitment to Advancing Innovative TherapiesNEW YORK, Aug.23, 2023(GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, is pleased to announce that it has appointed William A. Clementi, Pharm.D., FCP as Chief Development Officer. Dr. Clementi will formally take up the CDO role effective...
Nasdaq GlobeNewswire
23/08/2023

Medical Supplies Market size worth USD 165.1 Billion, Globally, by 2030 at 2.4%…

Download PDF Brochure: https://www.verifiedmarketresearch.com/download-sample?rid=144345 Download PDF Brochure: https://www.verifiedmarketresearch.com/download-sample?rid=144345 Browse in-depth TOCon" Medical Supplies Market " 202 - Pages 126 – Tables 37 – Figures Expanding Horizons: Global Medical Supplies Market Set for Robust Growth The global Medical Supplies Market is on the brink of a remarkable growth trajectory, driven by a confluence of factors that...
PR Newswire
23/08/2023

The ADC Technology Market is projected to grow at a CAGR of ~12% till 2035…

Despite the growing adoption, limitations of conventional antibody drug conjugates and related technologies, such as low safety and efficacy, unstable DAR and off-site toxicity, have prompted innovators to look out for more advanced antibody drug conjugate linker and conjugation technologies. Driven by the growing demand for antibody drug conjugates and the ongoing technological advancements, the ADC linker and conjugation technologies market is poised to experience noteworthy growth over the…
PR Newswire
23/08/2023

Optum Applauded by Frost & Sullivan for Advancing the Use of Real-World Evidence…

The combination of claims and EHR data, an expanding incorporation of genomic insights, and a continued emphasis on RWE and diversity, make Optum the partner of choice for biopharmaceutical (biopharma) companies seeking to create higher-value treatments while accelerating their time to market. The company is leading life sciences innovation and healthcare impact through consistent messaging, consulting services that leverage RWD assets, investments in new technology, stakeholder engagement, and…
PR Newswire
23/08/2023
Altri  Comunicati